Search

Displaying results 2951 - 2960 of 4262 in total
  1. Drug

    Bertilimumab

    go.drugbank.com/drugs/DB05429
    Investigational

    It is developed by MedImmune for the treatment of Allergic Rhinitis.

  2. Drug

    Topiroxostat

    go.drugbank.com/drugs/DB01685
    Investigational

    Topiroxostat and its metabolites are shown to be unaffected by renal complications, thus may be effective in patients with chronic kidney diseases [A19657].

  3. Drug

    Icodextrin

    go.drugbank.com/drugs/DB00702
    ApprovedInvestigational

    Icodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers. It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stag...

  4. Drug

    Potassium acetate

    go.drugbank.com/drugs/DB14498
    Approved

  5. Drug

    Potassium sulfate

    go.drugbank.com/drugs/DB14499
    Approved

  6. Drug

    Enprofylline

    go.drugbank.com/drugs/DB00824
    ApprovedWithdrawn

    Enprofylline is a derivative of theophylline which shares bronchodilator properties. Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and ...

  7. Drug

    Methazolamide

    go.drugbank.com/drugs/DB00703
    Approved

    A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.

  8. Drug

    Voglibose

    go.drugbank.com/drugs/DB04878
    Investigational

    It is made in India by Ranbaxy Labs and sold under the trade name Volix.

  9. Drug

    AZD-8186

    go.drugbank.com/drugs/DB15029
    Investigational

    investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by

  10. Drug

    2X-121

    go.drugbank.com/drugs/DB16063
    Investigational

    2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the